<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this report we present a patient with B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> who developed an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> after administration of the human anti-CD20 antibody IDEC-C2B8 (RITUXIMAB) in standard dose of 375 mg/m2 </plain></SENT>
<SENT sid="1" pm="."><plain>IDEC-C2B8 has been demonstrated to have only mild and tolerable side effects in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In these trials patients with <z:hpo ids='HP_0100827'>lymphocytosis</z:hpo> &gt;5000/microl were excluded </plain></SENT>
<SENT sid="3" pm="."><plain>Physicians must be aware of this hitherto unreported phenomenon in patients with high CD20-positive blood counts </plain></SENT>
</text></document>